Related Experiment Video
Updated: Aug 22, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
Anhedonia and neuropsychotropics: A pharmacovigilance-pharmacodynamic study
1Medical and Clinical Pharmacology, Faculty of Medicine, University Hospital, 31000 Toulouse, France.
Purpose:
Anhedonia is defined as inability to experience pleasure or enjoyment from activities normally pleasurable. Role of drugs in occurrence of anhedonia is little known. The study was performed to investigate, first associations between anhedonia and exposure to neuropsychotropics and, second potential pharmacodynamic mechanisms of this adverse drug reaction.
Methods:
The first part of the study used individual case safety reports (ICSRs) in adults registered in the global pharmacovigilance database, Vigibase®, between 01/01/2000 and 31/12/2024 with neuropsychotropics. Results are shown as reporting odds ratios (ROR) with their 95%CI. Second, we performed a pharmacovigilance-pharmacodynamic study using linear regression analyses to explore the association between anhedonia with antidepressants and binding affinities for their monoamine transporters.
Results:
Among 24,913,179 ICSRs, 1123 reported anhedonia with neuropsychotropics, mainly in females (52.5%) and between 18-44 years (55.6%). Significant associations were found with psycholeptics [ROR=1.23 (1.14-1.33), including second generation of antipsychotics and anxiolytics], psychoanaleptics [ROR=1.66 (1.52-1.82), including serotonin reuptake inhibitors and venlafaxine but not other antidepressants] and some other drugs like naltrexone, varenicline, duloxetine, clonazepam or oxycodone. No association was found for anesthetics, other analgesics, other antiepileptics, hypnotics/sedatives, or antiparkinsonians. Direct drug comparisons found significant ROR values for psychoanaleptics versus psycholeptics [1.35 (1.20-1.51)], for antidepressants versus antipsychotics [2.63 (2.24-3.09)] and for antidepressants versus anxiolytics [1.27 (1.11-1.45)]. No significant association was found between monoamine pKi values and occurrence of anhedonia with antidepressants.
Conclusion:
Among neuropsychotropics, serotonin reuptake inhibitors, benzodiazepine anxiolytics and antipsychotics are associated with anhedonia reports. We were unable to find any correlation between anhedonia reports with antidepressants and their direct effects on monoamine transporters.
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Therapeutic Drug Monitoring: Affecting Factors
Drug Abuse and Addiction: Pharmacological Phenomena
Pharmacodynamics: Overview and Principles
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
Pharmacodynamic Responses: Different Types
Pharmacodynamics in Geriatric Patients: Effects of Age

